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ABSTRACT

Prostate Cancer is the second most deadly cancer in men, after lung cancer. The need for
new and effective therapeutics that can constrain prostate cancer progression are challenged by
the lack of suitable delivery strategies that target prostate cancer tissue. To study CT20p as
potential chemotherapeutic agent in the treatment of prostate cancer we proposed the use of
targetable hyperbranched polyester (HBPE) based nanoparticles as delivery system. Folic acid
was conjugated to the nanocarrier to improve the selectivity of the nanoparticle towards specific
cell surface targets in prostate cancer cell lines. Specifically we evaluated LNCaP that upregulated the PSMA receptor. The synthesis of folate conjugated hyperbranched polyester
nanoparticles was accomplished using an aliphatic and biodegradable hyperbranched polyester
(HBPE). HBPE was prepared from commercially available diethyl malonate and 4-bromobutyl
acetate. Our AB2 type monomer displays a three-bond connectivity that grows threedimensionally under specific polymerization conditions. The product, HBPE, is a polymer with
globular configuration that contains surface carboxylic acid groups and holds hydrophobic
cavities. Carboxylated HBPE nanoparticles were synthesized via solvent diffusion method. A
variety of hydrophobic cargos including: dyes (DiR and DiI) and the cytotoxic peptide CT20p
were successfully encapsulated. DLS along with STEM imaging reveal nanoparticle preparations
with ~100 nm size. Using water-soluble carbodiimide chemistry, surface modifications were
accomplished. Available carboxylic acid groups were conjugated to aminated folic acid to yield
folate functionalized nanoparticles.
We explore the targeting capability of the Folate-HBPE nanoparticles and demonstrated
that the cell internalization of Folate-HBPE into prostate cancer cell lines (LNCaP and PSMA
iii

(+) PC-3) was attained via a PSMA-mediated targeting mechanism. Furthermore, when CT20p
was delivered to PSMA expressing PCa cells, detachment and death was observed; together with
a reduction in the levels of β1 integrin (CD29) expression, an integrin implicate in cell
communication and cell adhesion. CT20p inhibits cell proliferation within 24 h and produce
significant cell death after 48 h post treatment. The IC50 of CT20p was calculated at ~7 nM.
Additionally, we investigated the capability of Folate-HBPE(CT20p) to perform as a therapeutic
agent, in an in vivo setup, using a murine prostate tumor model. The Folate-PEG-HBPE NPs
protected CT20p while in circulation and allowed effective uptake by PSMA-mediated targeting.
Treatment with Folate-HBPE(CT20p) display localize tumor targeting and significant tumor
growth inhibition in PSMA(+) PCa cell lines within days. Together these results suggest the
potential of Folate-HBPE(CT20p) nanoparticles in the treatment of prostate cancer.
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CHAPTER ONE: INTRODUCTION

Introduction
Prostate Cancer and Current Treatment Alternatives
Prostate cancer (PCa), is the second cause of cancer deaths in Western men.1,2,3 In the last
decade, the occurrence of prostate cancer has gradually increased. The United States Centers for
Disease Control and Prevention (CDC) reported >200,000 new cases of PCa and >25,000 deaths
from prostate cancer last year. 1,2 Statistics point out that PCa is more frequent in black men and
Caucasians compare to Asians.4 The prostate, located on top of the rectum, is a gland within the
male reproductive system; in charge of secreting a seminal fluid that nourishes and protects the
sperm. There are different kinds of cells within the prostate, although when we refer to PCa most
likely we are referring to an adenocarcinoma. Additional uncommon forms of prostate cancer
included sarcomas, small cell carcinomas, among others. Nowadays, androgen depravation
therapy (hormonal castration) is the most common option when treating prostate cancer.5 Other
alternatives comprise chemotherapy with a variety of drugs (paclitaxel, doxorubicin, among
others), surgery or radiation therapy. The down side of androgen deprivation treatment is its
severe side effects that involve: low libido, impotence and urinary incontinence. Additionally,
most cases develop castration resistance over time. While localized PCa can be treated by
subtraction of tumor, none these alternatives is very efficient when treating the disease at the
metastatic stage. While the tumor is growing, with time it becomes less organized, losing its
structural organization and eventually invading the surrounding tissues. Although neoplastic
transformation starts anchor to the gland, malignant cells eventually metastasize. This invasion is
know as metastasis; in the case of PCa, the disease tend to metastasize to the lymph nodes,
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bladder, and bone.6 Metastatic castration-resistant prostate cancer treatments only prolong life
for a few weeks or months. Hence there is a necessity for the development of new powerful antimetastatic castration-resistant PCa treatments. Essentially, there is the need for the design new
effective treatments that can overcome current limitations including: systemic toxicity due to
poor cancer cell-specific targeting.

Challenges and New Approach
In prostate cancer, Prostate-Specific Antigen (PSA) has been extensively used as a
maker/tool for diagnosis, before and after castration. However, androgen depravation (surgically
or medically) causes a reduction of PSA in serum levels and tissue, due to a decrease in the
testosterone, which is required in the production of PSA.7 Nowadays most approaches for the
treatment and diagnosis of PCa relied on prostate specific antigen (PSA). Nevertheless,
challenges including the low specificity led to miss-treatment at early stages of the disease or
miss-treatment to not expressing but more aggressive types of PCa.8 A marker whose activity is
not compromise after chemical or surgical castration can be used to monitor the progression of
the tumor and as a target in therapies for the metastatic castration-resistant PCa. In the other
hand, Wright and collaborators establish that PSMA expression is up regulated even after
androgen deprivation; making this receptor a key target when considering alternatives in the
treatment and diagnosis of metastatic castration-resistant PCa. PSMA expression has been
identified in normal prostate tissues as well as in prostatic neoplasia, and more interestingly in
metastatic carcinomas.9,10 Also, PSMA is present at low levels of expression in the small
intestine, proximal renal tubules, and salivary glands.11 Different from benign tissues, it has been
shown that PSMA is up-regulated in the secretory cells of the prostate epithelium.12 Other than
PCa, PSMA can be found in the neo-vasculature (new vasculature created by the tumor) of
2

several solid tumors but not in normal blood vessels.12 Moreover, PSMA is not only associated
to a restricted tumor area but is know to be overexpress in later stage of the disease including
metastatic PCa.13,14,15 For these reasons, PSMA has been validated as promising target in
diagnosis and treatment of PCa.

Prostate Specific Membrane Antigen (PSMA)
Prostate specific membrane antigen, a well-validated prostate cancer cell membrane
protein was initially describe in the mid 90’s.16,17 PSMA is a type II membrane glycoprotein with
a molecular weight of ~100 kDa. Its structure comprises: ~18 amino acids in the intracellular
portion, ~19 amino acids within the transmembrane domain and ~707 amino acids in the
extracellular domain.

18,19,20

Figure 1 shows and schematic representation of prostate-specific

membrane antigen (PSMA) structure reported by Rajasekaran et.al. PSMA is involved in the
enzymatic cleavage of polyglutamed folate. This receptor is not only recognize to possess folate
hydrolase (FOLH) activities but N-acetylated and γ -linked acidic dipeptidase functions
(NAALADase).21,22 Interestingly PSMA functions as a folate hydrolase, enabling the generation
of free folate and succeeding folate uptake. Typically PSMA internalization happens via
endocytosis from the plasma membrane. This process arises from first five amino acids from the
NH2-terminal within the intracellular portion. Though, PSMA-mediated internalization occurs
thru the extracellular domain.23,24
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Figure 1.Proposed prostate-specific membrane antigen (PSMA) structure.20

Leek et.al demonstrated that LNCaP, a prostate cancer cell line originated from a
metastatic lymph node, expressed PSMA. However, other prostatic cancer cell lines DU-145 or
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PC-3 did not. Should be noted that when studying the PMSA receptor LNCaP, DU-145 and PC-3
are frequently used.17

Targeting PSMA
The specific expression of PSMA in PCa and its function validates this receptor as a
potential target in the study for alternatives in cancer therapy. Recently researches had explored
alternatives routs including immunotherapy and immunodetection applying anti-PSMA
antibodies.

16, 25, 26

For example, ProstaScint® was the first clinical agent for the targeting

PSMA exclusively for PCa.12 Also anti-PSMA J591 antibody as been reported to be well
tolerated by patients during phase I of clinical trials.25, 27 PSMA can be used as a diagnostic tool,
it has been reported the targeting of PSMA using radiolabel urea-based small molecules. The
uses of this type construct allows for the imaging of the tumor, making this a potential tool for
diagnosis and prognosis all stage of PCa.18 Targetable approaches are more efficient than the
enhanced permeability and retention (EPR) effect due to a major accumulation at tumor
locations. Additionally, the broad distribution of drugs may result in toxicity to healthy organs.
Cancer-cell specific target offers a world of difference between current chemotherapy
alternatives, where the systematic cytotoxicity is a challenge. For instance the identification of
new targets for the PSMA receptor have driven scientist around the world to look at small
molecules that can be conjugated to the surface of different types of delivery vehicles to offers a
more specific release of the drug. The decoration of the nanovehicle exterior with assorted
ligands has been shown to stimulate a targeted delivery in to tumor area improving molecular
uptake.28,29,30,31 Besides the targeting agents, it is important to consider the delivery vehicle that
can protect the therapeutic agent while in circulation. Numerous multifunctional delivery
systems have been described.32,33,34 For example, micelles and polymeric structures offered
5

unlimited possibilities when encapsulating hydrophobic molecules, offering water stability and
longer circulation times in the system..

Therapeutic Peptides
Developing peptides as therapeutic agents for cancer therapy is field that creates new area
to explore in addition to advantages when compared to small molecule drugs. Peptides developed
from known proteins might reduce off-target effects and decrease chances of developing drug
resistance, resulting in low systematic toxicity. Peptides can be produce and modify
conveniently. One approach is to originate peptides from previously characterized, endogenous
cellular proteins. Recently, CT20p has been pointed as a novel cytotoxic peptide that targets
cancer-specific differences.35,36,37 CT20p has the potential to obstruct cancer cell invasiveness,
making the peptide a promising agent for inhibting metastasis. CT20p is a 20 amino acid

lpha

helical peptide developed from the α9 transmembrane domain of Bax. This peptide, henceforth
referred to as CT20p, is amphipathic and shares similarities with anti-microbial peptides
(AMPs). While derived from an apoptotic protein and retaining cytotoxic activity, CT20p, due to
its inherent features, may have unique actions unrelated to the parent protein that could have
significant clinical impact.

6

CHAPTER TWO: MATERIALS AND METHODS

Materials
Acetonitrile, potassium carbonate (K2CO3), ethyl acetate, Sodium sulfate (Na2SO4),
petroleum ether, hexane, Chloroform-d (CDCl3), methanol, Potassium Hydroxide (NaOH),
hydrochloric acid (HCl), Phosphate Buffered Saline (PBS) 10X, chloroform (CHCl3) were
acquired from Thermo Fisher Scientific. Dimethyl sulfoxide (DMSO), dimethylformamide
(DMF), N- hydroxysuccinimide (NHS), 4-bromobutyl acetate, p-toluenesulfonic acid (PTSA),
Diethyl malonate and doxorubicin Hydrochloride (Doxo) were purchased from Sigma-Aldrich.
Nitrogen gas (N2) [Industrial grade] and Carbon Dioxide gas (CO2) [Coleman grade] were
purchased from Air liquid. EDC (1-ethyl-3-[3-(dimethy- lamino)propyl] carbodiimide
hydrochloride) was obtained from Pierce Biotechnology. Reagents were used as received, unless
indicated otherwise. Near Infrared dyes (DiI-D282, and DiR-D12731) and 6-diamidino-2phenylindole (DAPI-D1306) were purchased from Invitrogen. Dialysis membranes (MWCO 68K, 23 mm Flat-width) were obtained from Spectrum Laboratories, sterile syringe filters (0.22
µm

pore

size)

were

purchased

from

Millipore.

3-(4,5-dimethylthiazol-2-yl)-2,5-

diphenyltetrazolium bromide (MTT) and 4’,6-diamidino-2-phenylindole (DAPI-D1306) were
purchased from Invitrogen. Hydrochloric acid and Isopropanol were purchased from Thermo
Fisher Scientific. RAW 264.7 (TIB-71PC3) cells, PC-3 cells (CRL-1435) and LNCaP cells
(CRL-1740) were obtained from American Type Culture Collection (Manassas, VA).
Transformed PSMA (+) PC-3 cells were obtained from Dr. Jam Grimm (Memorial-Sloan
Kettering Cancer Center, New York, NY). Dulbecco's Modified Eagle's Medium (DMEM),
F12K, RPMI-1640 basal medias, Trypsin (0.25% Trypsin in HBSS without calcium and
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magnesium Porcine), penicillin–streptomycin and Corning Matrigel Matrix High Concentration
(HC) were acquired from Cellgro (Manassas, VA, USA) and FBS, fetal bovine serum, from
American Type Culture Collection (Manassas, VA). Paraformaldehyde, 16% w/v aq. soln., was
obtained from Alfa Aesar (Ward Hill, MA). Puromycin was purchased from Invivogen. Poly-Dlysine hydrobromide, suitable for cell culture came from Sigma Aldrich. Violet Ratiometric
Apoptosis

kit

purchased

from

Invitrogen

(Carlsbad,

CA,

USA).

CT20p

(Ac-

VTIFVAGVLTASLTIWKKMG-NH2), Biotin-tagged CT20p and RHO-tagged CT20p were
commercially synthesized (Biopeptide Co., Inc, San Diego, CA, USA) at > 98% purity.
Foxn1nu/Foxn1nu nude mice purchased form Charles River (Troy, NY, USA). Our group
synthesized doxo-ss-Folate previously. FITC labeled mouse anti-human CD61 and PE labeled
mouse anti-human CD29 were purchased form BD Bioscience (San Jose, CA, USA). Mouse
monoclonal anti-CCTβ was acquired from Millipore and rabbit polyclonal anti-p38 from Santa
Cruz Biotechnology (Dallas, TX, USA). Secondary antibodies conjugated to IRdye800CW were
obtained from Li-cor (Lincoln, NE, USA). PMPA (NAALADase inhibitor) was purchased from
Tocris Bioscience (Bristol, United Kingdom).

Characterization
Analytical Thin Layer Chromatography (TLC) was performed on glass plates coated with
silica gel GF 254 and were developed in iodine vapor. TLC plates, Silica Gel; Layer Thickness:
200 μm were acquired from Selecto Scientific. Column chromatography was performed using
silica gel (100-200 mesh), and the eluent is described below for each step. UV-Vis spectra were
acquired using a CARY 300 Bio UV-Vis spectrophotometer. Infrared spectra were recorded on a
Perkin Elmer Spectrum100FT-IRspectrometer. 1H NMR spectra were recorded on a Varian
VNMRS 500 MHz spectrometer holding a magnet Oxford 11.7T 51mm Unshielded. In addition,
8

the TMS/solvent signal was used as an internal reference. Transmission Electron Microscope
imaging was done in a JEOL TEM-1011, with a tungsten filament and a 0.4 nm point-to-point
resolution. Dynamic light Scattering (DLS) measurements were completed using a Zetasizer
Nano ZS (Malvern Instruments). Flow Cytometry experiments were completed using a BD
FACS Calibur multipurpose flow cytometer system from BD Biosciences. MTT cell viability
assay and cell adhesion assay were done using the Biotek Synergy HT multi-detection
microplate reader. Ultrasound imaging and measurements were done on Visual Sonics Vevo
2100 (Toronto, ON, Canada). Fluorescence microscopy was performed using an Olympus IX71
microscope equipped with a 40x and 10x objective. Flow Cytometry data was analyzed using
FCS Express software (Denovo, Niwot, CO, USA).

Cell Culture and Mice
RAW 264.7 cells were grown in Dulbecco's Modified Eagle's Medium (DMEM)
modified to contain 4 mM L-glutamine, 4500 mg/L glucose, 1 mM sodium pyruvate, and 1500
mg/L sodium bicarbonate, 10% FBS and 1% penicillin–streptomycin. LNCaP cells were
maintained in RPMI 1640 basal media supplemented with 10% FBS and 1% penicillin–
streptomycin. In addition, all plates were pre-treated with poly-D-lysine. Briefly, 50 mL of
sterile DI water were added to 5 mg of poly-lysine, and culture surfaces were coted with 1.0
mL/25 cm2. A gently shake ensured an even coating of the culture surface. The culture surface
was incubated for 20 minutes at 37°C and 5% CO2. After removing the solution by aspiration,
the coated surface was rinse 2 times with PBS buffer and allowed to dry for 2 hours before used.
Besides, PC-3 cells were grown in F12K basal media supplemented with 10% FBS and 1%
penicillin–streptomycin, whereas PSMA(+) PC-3 cells were maintained in F12K supplemented
with 10% FBS and 1% penicillin–streptomycin and 0.05% puromycin was added to ensure the
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selection of the cell line. Cells were grown at 37°C with 5% CO2. Nude mice Foxn1nu/Foxn1nu
were maintained in accordance with Guide for the Care and Use of Laboratory Animals of the
National Institutes of Health.

Synthesis of Hyperbranched Polyester (HBPE)
Synthesis of diethyl 2-(4-acetoxybutyl)malonate
Diethyl malonate (10 g, 62.5 mmol) and 4-bromobutyl acetate (15.84 g, 81.3 mmol) were
placed in a 250 ml round-bottom flask containing 120 mL acetonitrile. The reaction mixture was
stirred for 2 min at room temperature followed by the addition of potassium carbonate (34.5 g,
250.1 mmol). The reaction mixture was heated at 90°C and refluxed for 36 hours, as shown in
Figure 2. After 36h TLC (30% ethyl acetate in hexane) was use to confirm product formation.
Then the reaction mixture was filtered, and the solid was discarded and the filtrate was
concentrated to collect a yellow liquid. The product was extracted with ethyl acetate, and washed
with water twice. The organic layers were combined and dried over anhydrous sodium sulfate
(Na2SO4) crystals. The product was clean through column chromatography using 30% ethyl
acetate in Hexane as the eluent. Progress of the separation was followed utilizing TLC, and the
final product was collected and confirm by proton NMR.

10

Figure 2.Synthetic scheme diethyl 2-(4-acetoxybutyl)malonate.

Synthesis of 2-(4-Hydroxybutyl)malonic Acid
50 mL of methanol and diethyl 2-(4-acetoxybutyl)malonate (5.0 g, 18.25 mmol) were
placed in a 100 mL round-bottom flask and stirred at room temperature for 2 min. An aqueous
solution of NaOH (2.1 g, 54.74 mmol in 7 mL of water) was added and kept under continuous
stirring at 90 °C. After 8 h the reaction mixture was brought to room temperature, and followed
by the dropwise addition of dilute hydrochloric acid until the reaction mixture reached pH 2-3,
Refer to Figure 3. The protonated monomer along with the reaction mixture was concentrated
using rotary evaporator under vacuum. In order to remove excess hydrochloric acid, 50 mL of
chloroform were added and Nitrogen gas was bubbled through the solution heated at 60 °C.
Additional chloroform was added as needed until the acidic gas stops emerging. The mixture
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was filtered, concentrated and clean using column chromatography and 10% methanol in
chloroform as eluent. Progress of the separation was followed using TLC and the final product
was collected and confirmed by H NMR.

O

O

1.MeOH,
NaOH

O

90°C,8h

O

O
O

2. diluted HCl
(bring pH 2-3),
Troom

diethyl 2-(4-acetoxybutyl)malonate

O
OH

HO
HO

O

2-(4-hydroxybutyl)malonic acid
AB2 Monomer

Figure 3.Synthetic scheme of diethyl 2-(4-Hydroxybutyl)malonic Acid.

Synthesis of Hyperbranched Polyester (HBPE)
The one-step synthesis, shown in Figure 4, comprises the condensation of the AB2 type
monomer. This functional AB2 monomer, under polymerization conditions, grows three
dimensionally forming a highly branched polymeric structure. The monomer and the catalyst
PTSA (100:1 molar ratio) were placed into a 10 mL round-bottom flask and dried under vacuum
for 30 minutes. Vacuum was release, then the vessel was fill with nitrogen gas and heated at 150
°C for 2 h. The progression of the polymerization was confirmed by the production of water
vapor, clearly visible after condensation. Subsequently the melted reaction’s atmosphere was
changed from nitrogen to vacuum for 1 h, while keeping the polymerization temperature.
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Figure 4.Synthetic scheme of HBPE.

Furthermore, the polymer was cleaned as described in Figure 5. The polymer was
dissolved in DMF and precipitated in water, followed by centrifugation of the mixture at 1500
rpm for 15 min. The supernatant was discarded, and the pellet (polymer) was washed one more
time and dried under vacuum to obtain the pure polymer.

Rapid addition
of DI H2O

Addition of
DMF

Clean
HBPE Pellet

HBPE in
DMF

HBPE Pellet

Centrifuge
at 1500 rpm

Figure 5. Schematic diagram for the step-by-step cleaning of HBPE.

Thin-Layer Chromatography (TLC)
Regarding the progress of the synthesis and purification of diethyl 2-(4acetoxybutyl)malonate (Figure 2) and 2-(4-Hydroxybutyl)malonic Acid (Figure 3); TLC was the
technique selected to monitor the progress of the synthetic and cleaning steps. TLC is a simple,
fast, and low-cost method that provides a rapid response, including the number of components
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within a sample/mixture. Briefly, a small spot of solution containing the sample, as shown in
Figure 6,was spotted onto silica gel-coated TLC plate, about 2.0 centimeter from the base of the
plate. The solvent was allowed to completely evaporate after the sample was spotted. The TLC
plate was subsequently developed in a chamber containing the mobile phase that gradually
ascended the plate drive by the capillary action. Furthermore, the selection of the mobile phase
was based on the components in the reaction mixture. 30% of ethyl acetate in hexane and 10%
methanol in chloroform where chosen as the mobile phase for the examination of diethyl 2-(4acetoxybutyl)malonate and 2-(4-Hydroxybutyl)malonic respectively. After the TLC was
developed the visualization of the components was enhanced through the staining with iodine
vapors, suitable for staining of unsaturated and aromatic compounds.

30% ethyl acetate in hexane

STD

BBA

Ptd

10% methanol in chloroform

SM (Ptd)

DEM

(A)

Ptd2

STD

(B)

Figure 6.A) Diagram of diethyl 2-(4-acetoxybutyl)malonate (Ptd) TLC plate. Including
standard (STD), starting materials: 4-bromobutyl acetate (BBA) and diethyl malonate
(DEM) and the product (Ptd) utilizing 30% of ethyl acetate in hexane as the mobile phase.
B) Diagram of 2-(4-Hydroxybutyl)malonic (Ptd2) TLC plate. Including product standard
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(STD), starting material (SM)/(Ptd) : diethyl 2-(4-acetoxybutyl)malonate and the product
(Ptd2) using 10% methanol in chloroform as the mobile phase.

Nuclear Magnetic Resonance (NMR)
1

H NMR spectra were recorded on a Varian VNMRS (500 MHz) spectrometer. In

addition, the TMS/solvent signal was used as an internal reference.

Synthesis of Cargo-Encapsulating Polymeric Nanoparticles
Water-Based Solvent Diffusion Method
All nanoparticles used in the study were synthesized as described below. 5 μL of 1.0
μg/μL solutions of near IR dyes (DiI or DiR) or cytotoxic peptide (CT20p or Rho-CT20p)
dissolved in DMSO and 50:50 DMSO/H2O respectively, were mix in 250 μL of DMF were
separately mixed into 250 μL of DMF solution containing 15 mg of 30 mg/mL hyperbranched
polymers. For a ratio of ~ 0.33 μg peptide: 1 mg nanoparticles. The resulting mixture,
polymer/cargo dissolved in DMF, was added drop-wise to deionized water (5 mL) under
continuous stirring (vortex at 1250 rpm) at room temperature; developing cargo encapsulated
HBPE nanoparticles as shown in Figure 7. For empty/naked nanoparticles this same protocol was
followed. This process results in the formation of carboxyl-functionalized spherical HBPE
nanoparticles suspended in an aqueous solution that can be easily functionalized with
carbodiimide chemistry. The resulting COOH-HBPE nanoparticles were clean by dialysis
(MWCO 6-8K) against PBS solution (pH = 7.4) and sterilize using a 33 mm diameter sterile
syringe filter with a 0.22 µm pore size. The preparations were stored in the refrigerator at 4°C
for further characterization and subsequent analysis.
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Figure 7.Representation of water-based solvent diffusion method.

Synthesis of Functional HBPE Nanoparticles
Surface Modification via Water-Soluble EDC/NHS Chemistry
Folate decorated HBPE nanoparticle were prepared after carboxylated HBPE
nanoparticles and aminated folic acid. Folic acid was modified as shown in Figure 8, following a
procedure previously described by Zhang et al.30 Das and collaborators29. Briefly, a 50 ml round
bottom flask was placed under high vacuum for 2 minutes; the reaction vessel was purged with
nitrogen. A nitrogen atmosphere is required to ensure dry conditions. Afterward, 250 mg of folic
acid were dissolved in 25 mL of dry DMSO. Next, 140 mg of DCC were added, followed by 130
mg of NHS. The reaction mixture was stirred and heated at 50°C for 6h. Dicyclohexylurea
(DCU), a white precipitate, was produced and removed by gravity filtration (Whatman, 150
mm). An excess (68.1 mg) of ethylene diamine (EDA) was added dropwise to the activated folic
acid and stirred overnight at room temperature in presence of 400 uL of pyridine as catalyst.
Afterwards, an excess of cold acetonitrile was added to precipitate NH2-folate. The amine
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functionalize folate was isolated via vacuum filtration and dried in the oven at 80°C. The product
had a characteristic dark yellow color.
O
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H2 N

N

OH

N
H

O
HN

OH

O

N
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N
1.DCC, NHS, DMSO
50 °C, 6h
2. Pyridine, DMSO, H2N
O

N
H

O
N

HN
H2N

N

O

N
H

NH2

OH
H
N
O

NH2

N

Figure 8.Synthetic scheme of NH2-Folate.

Folic acid decorated HBPE nanoparticles were synthesized following a procedure
previously described by Santra et al.28,31. Specifically, a solution of 10 mmol of EDC in 200 μL
of MES buffer was added dropwise to an aqueous solution containing 1.0 mol of carboxylated
HBPE nanoparticles. Followed by, the dropwise addition of 10 mmol NHS in 200 μL MES
buffer. After 3 min incubation at room temperature, a solution of 10 mmol of aminated folic acid
in water was added dropwise and followed by continuous stirring for 3 h, as displayed in Figure
9.The resulting Folate-HBPE nanoparticles were clean by dialysis (MWCO 6-8K) against PBS
solution (pH = 7.4) and sterilized sing a 33 mm diameter sterile syringe filter with a 0.22 µm
pore size. The preparations were stored at 4°C or further characterization and subsequent
analysis.
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Figure 9.A) Schematic representation of the conjugation of NH2-Folate onto the surface of
carboxylated Hyperbranched Polyester (HBPE-NPs). B) Conjugation of folate to
carboxylated-HBPE nanoparticles via an ethylenediamine linker.

Similar to folic acid decorated HBPE nanoparticles, the addition of PEG was preformed
via EDC/NHS chemistry. Likewise, a solution of 10 mmol of EDC in 200 μL of MES buffer was
added dropwise to an aqueous solution containing 1.0 mol of COOH-HBPE nanoparticles.
Followed by, the dropwise addition of 10 mmol NHS in 200 μL MES buffer. After 3 min
incubation at room temperature, a solution of 10 mmol of Amine-PEG4- Carboxy (NH2-PEG4COOH) in water was added dropwise and followed by continuous stirring for 3 h as describe in
Figure 10 section A. Since Carboxy-PEG4-Amine has available an amino terminal it reacts with
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the exposed carboxylic acid group in the surface of the nanoparticle forming an amide bond. The
designated compound Carboxy-PEG4-Amine contains four polyethylene glycol units with a
molecular weight of 265.30 g/mol. The resulting pegylated HBPE nanoparticles were purified by
dialysis (MWCO 6-8K) against PBS solution (pH = 7.4) and sterilized using a 33 mm diameter
sterile syringe filter with a 0.22 µm pore size. The preparations were stored at 4°C for further
characterization and subsequent analysis. Folic acid was added to pegylated HBPE nanoparticles
using the same approach as describe above. Although, 10 mmol of NH2-Folate were added
instead of 10 mmol of Carboxy-PEG4-Amine as shown in Figure 10 section B. The preparations
were stored at 4°C for further characterization and subsequent analysis.
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Figure 10.Schematic representation of the conjugation of: A) Carboxy-PEG4-Amine onto
the surface of carboxylated HBPE nanoparticles. B) NH2-Folate onto the surface of
pegylated HBPE nanoparticles.

Characterization of Functional HBPE Nanoparticles
Transmission Electron Microscopy (TEM) Imaging
We examined the size and the morphology of the Fol-CT20p-HBPE NPs by transmission
electron microscopy (TEM) using a JEOL TEM-1011 with 1 drop of the preparation solution
mounted on a thin film of amorphous carbon deposited on a copper grid.

Dynamic Light Scattering Measurement
To determine the effective size and size distribution of the Folate-HBPE and COOH20

HBPE nanoparticle suspensions were submitted to dynamic light scattering (DLS) using a
Zetasizer Nano ZS. HBPE nanoparticles were dispersed in 1 mL nanopure water. The solutions
were filtered through a 0.2-μm-syringe filter membrane to remove any impurities and then
directly analyzed.

Measurement of UV-Vis Spectra
We measured the absorption maximum of the free Dyes: DiI (550nm), and DiR (750nm)
in addition to encapsulated Dyes (DiI, or DiR) within COOH-HBPE NPs to confirm the presence
of the dye encapsulated in the nanoparticle. The presence of folic acid on the surface FolateHBPE NPs was confirmed by UV-Vis with a maximum absorption at 363 nm. Spectra were done
using a CARY 300 Bio UV/Vis spectrophotometer. A scan form 350 nm to 800 nm was recorded
for all the samples.

In Vitro drug/dye release
We investigated the in vitro drug/dye release from the polymeric nanocavities of the
Folate-HBPE nanoparticles, very relevant when studying the construct therapeutic applications.
To evaluate the Folate-HBPE nanoparticles drug release profile, we implemented a low-pH
degradation experiments using a dynamic dialysis method previously reported by our research
group31. Exactly 100 μL of Folate-HBPE (RHO-CT20P) nanoparticles were mixed with 20 μL of
diluted solutions of hydrochloride acid of pH 5 or pH 7.5. The mixtures were then incubated in a
dialysis bag (MWCO 6-8 K) at a temperature of 37°C and placed in a beaker containing a PBS
solution of pH 7.4. The amount of free RHO-CT20p released from the nanoparticle into the PBS
solution was documented at different time intervals between 0 to 24 hours. Aliquots of 1 mL
each were removed from the PBS solution and measurements of fluorescence intensity at ~ 627
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nm for RHO-CT20p were recorded. The concentration of the RHO-CT20p was estimated using a
calibration curve. The cumulative fraction of release against time was calculated applying Equati
on 1. Where [cargo]t is the amount of RHO-CT20p released at time t, and [cargo]total is
the total RHO-CT20p that remained in the Folate-HBPE nanoparticles.

Equati on 1

(1)

In Vitro Cell Studies
FACS (Fluorescence-activated cell sorting) analysis
The assessment of targeting and PSMA-mediated cell internalization of FolateHBPE(DiI) NPs was done by FACS. Briefly, PC-3, PSMA(+) PC-3 or LNCaP cells were seeded
in on a 35-mm plates at a density 3 × 105 cells/well and grown until reaching confluence (~50%).
Subsequently, the wells were rinsed with sterile 1X PBS and 1.5 mL of the corresponding fresh
media was added and incubated with Folate-HBPE(DiI) or controls as labeled in legends. Plates
were treated with 35 μL [2.0 mg/mL, 0.02μg of DiI:mg of Nanopartilce] of the NPs suspension
and incubated at 37 °C in 5% CO2 for a 24 h period. PMPA was added an hour prior treatment in
excess, 100X treatment amount (~1 μM), if applicable. Media was collected and 500 uL of
0.05% trypsin was added and incubated until cell detachment. Both fractions were combined and
centrifuged at 1000 rpm; the cell pellets were collected and suspended in 1X PBS; and the
cellular suspensions were examined using a FACS Calibur flow cytometer (BD Biosciences).
PC-3, PSMA(+) PC-3 or LNCaP cells were collected at a final concentration of 1 × 106 cells/ml
and assayed using the Fol-HBPE(DiI) and Ethidium bromide (EtBr). Fluorescence was measured
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at 616 nm for EtBr (FL2) and at 565 nm for Dil fluorescence (FL1). Analysis of data was done
using FSC Express software (DeNovo). The acquisition number of the cells was set at 10,000.
Similarly, short-term survival was assessed using the flow cytometry based Sytox
AADvanced and Violet Ratiometric Membrane Asymmetry Probe, 4’-N,N-diethylamino-6(N,N,N-

dodecyl-methylamino-sulfopropyl)-methyl-3-hydroxyflavone

(F2N12S).

Violet

Ratiometric Membrane Asymmetry Probe/Dead Cell Apoptosis Kit was used according to the
manufacturer’s protocol (Invitrogen, Carlsbad, CA, USA). Briefly, RAW 264.7, PC-3, PSMA(+)
PC-3 or LNCaP cells were seeded in on a 35-mm plates at a density 3 × 105 cells/well and grown
until reaching confluence (~50%). Subsequently, the wells were rinsed with sterile 1X PBS and
1.5 mL of the corresponding fresh media was added. Plates were treated with Folate-HBPE
(CT20p) (7 nM), Doxo (1.2 μM), Doxo-ss-Folate (1.2 μM) or controls as labeled and incubated
at 37 °C in 5% CO2 for a 48 h period. The dose of CT20p, Doxo and Doxo-ss-Fol that kills
~50% of the cells in 48 h was determined to be ~7 nM (70 μg nanoparticles/1.5 ml), 1.2 μM and
1.2 μM correspondingly. PMPA was added an hour prior treatment in excess 100X treatment
amount (~1 μM). Media was collected and 500 μL of 0.05% trypsin was added and incubated
until cell detachment. Both fractions were combined and centrifuged at 1000 rpm, the cell pellets
were collected and suspended in 1X PBS and the cellular suspensions were examined using a
FACS Calibur flow cytometer.

Cell Viability Studies: MTT assay
MTT [3-(4,5-dimethylthiazlo-2-yl)-2,5-diphenyltetrazolium bromide] cell viability assay
was used to test the effect of Folate-HBPE(CT20p) NPs on the cell proliferation of PC-3, PSMA
PC-3 and LNCaP cell lines.

Specifically, PC-3, PSMA(+) PC-3 and LNCaP cells (2,500

cells/well) were seeded in 96-well plates, in 200uL of there corresponding culture medium. The
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cells were incubated for 24 h in the incubator (37°C, 5% CO2). Afterwards, the culture media
was replaced with fresh media (200 μL) including the Folate-HBPE(CT20p) at indicated
concentrations. For example, 3.5 μL of Folate-HBPE(CT20p) 2.0 mg/mL [0.02μg of CT20p: mg
of nanoparticle] for a final concentration of 7 nM of CT20p. Subsequently, each well was
washed three times with 1X PBS and treated with 20 μL of MTT solution (5 μg/μL).
Additionally the cells were incubated for 4 h in the incubator (37°C, 5% CO2). The resulting
formazan crystals were dissolved in acidified isopropanol (10:1 isopropanol:0.1 N HCl) at room
temperature. The absorbance measured at 570 nm using a Synergy HT multi-detection
microplate reader. These experiments were performed in triplicates and the control experiments
were carried out in the same way as described above, except that no treatment was added. The
percentage of cell survival as a function of CT20p concentration was later plotted to determine
the relative IC50 value, which stands for the CT20p concentration needed to prevent cell
proliferation by 50%.

Fluorescence Microscopy
To confirm receptor-mediated uptake of the Folate-HBPE(DiI) NPs and FolateHBPE(CT20p/DiI) NPs, we seeded PC-3, PSMA(+) PC-3 and LNCaP cell lines on a 35-mm
culture plate at a density 3 × 105 cells/well. When the plates reached a confluence ~50% the
wells were rinsed with sterile 1X PBS and 1.5 mL of the corresponding fresh media was added.
Plates were treated with 35 uL [2.0 mg/mL, 0.02μg of CT20p/DiI or DiI:mg of nanoparticle] of
the NPs suspension and incubated at 37 °C in 5% CO2 for 24h or 48h. The dose of CT20p (2.14
kDa) that kills ~50% of the cells in 24 h was determined to be ~7 nM (70 μg nanoparticles/1.5
ml). PMPA was added an hour prior treatment in excess, 100X treatment amount (~1 μM), if
applicable. After incubation, the cells were washed two times with 1X PBS and fixed with a 4%
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paraformaldehyde solution followed by nuclei staining with DAPI. Nuclear staining with DAPI
was performed as recommended by the supplier. The uptake of the cells was examined with a
florescence microscope equipped with a 10x or 40x objective. Multiple fluorescence images
were obtained, achieving a representative view of the cell-Folate-HBPE(CT20p/DiI) interaction.

Cellular Adhesion Assay
Crystal violet adhesion assay was done as described below. Detailed, PC-3, PSMA(+)
PC-3 and LNCaP cells were seeded in 96 well plates at a density of 15,000 cells/well succeeding
treatment with Folate-HBPE(CT20p) for 6h, 24h and 48h. Cells were allowed to gently shake for
15 sec, then fixed using 4% paraformaldehyde and washed twice with PBS 1X. Afterward the
cells where stained using an aqueous solution of crystal violet (5 mg/ml). After 30 min the plates
where washed twice with DI water. Absorbance at 595 nm was read on a Synergy HT multidetection microplate reader (Biotek).

Measurement of cell surface Integrin expression
PC-3, PSMA(+) PC-3 and LNCaP cells were plated in a 35 mm (6 well) plate and treated
with Folate-HBPE(CT20p) NPs (7nM) for 24 h and 48 h. Next the cells were trypsinised,
washed with PBS 1X and stained with FITC labeled mouse anti-human CD61 and PE labeled
mouse anti-human CD29, or appropriate FITC and PE isotype controls. Data was acquired with
an Accuri C6 flow cytometer and analyzed using FCS Express software.

In vivo studies
Corning Matrigel Matrix High Concentration (HC) was used to aid tumor growth. PC-3
and PSMA(+) PC-3 cells were prepared in a 50/50 mixture of plain F12-K media and Matrigel
Matrix HC. PC-3, PSMA(+) and PC-3 cells were harvested from culture and 1.5 million cells in
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100 μL Matrigel mixture were delivered subcutaneously into the flank region of 6-10 week-old
males, Foxn1nu/Foxn1nu nude mice. Each mouse received PC-3 in the left flank and PSMA(+)
in the right flank. Tumor volume and growth was evaluated by ultrasound. Moreover, 10 days
and 14 days following tumor injection mice bearing tumors received Folate-HBPE(CT20p) NPs
intravenously (IV). Each injection contained 20 μg of CT20p. Following CT20p injections,
tumors were measured daily with calipers in x and y dimensions. On the first day of the injection
and 10 days post injection the tumor area was assessed by 2-dimensional ultrasound by
measuring height and width of tumors. For tissue staining, a standard Hematoxylin and eosin
(H&E) protocol was implemented. A certified pathologist performed the histological
examination.
Likewise, LNCaP cells were prepared in 50/50 mixture of plain RPMI and Matrigel
Matrix HC. LNCaP cells were harvested from culture and 2 million cells in 100 μL Matrigel
mixture were delivered subcutaneously into the flank region of 6-10 week-old males,
Foxn1nu/Foxn1nu nude mice. Each mouse received LNCaP in the flank. Tumor volume and
growth was evaluated by ultrasound. CT20p treatments began 20 days after tumor injections.
Mice bearing tumors received Folate-HBPE(CT20p) NPs or PBS (control) intravenously (IV)
every 4 days. Each injection contained 150 μg of CT20p/PBS. Caliper measurements were taken
daily. Mice were weighed at the completion of the experiment. Tumors were removed and
weighted as well. This study was prepared in understanding with the recommendations in the
Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The
Institutional Animal Care and Use Committee at the University of Central Florida approved the
animal study protocol.
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CHAPTER THREE: RESULTS AND DISCUSION

Synthesis of Hyperbranched Polyester (HBPE)
HBPE was prepared in a 3-step synthesis; where diethyl malonate was specifically monoC-alkylated when reacted with 4-bromobutyl acetate. Resulting in the synthesis of diethyl 2-(4acetoxybutyl)malonate. To control the monosubstitution a weak base (K2CO3), a 1:1 ratio of
diethyl malonate and 4-bromobutyl acetate were required. If a strong based (KOH or NaOH) was
used instead of the weak base, the formation of a di-substituted product would be favored. Disubstitution is unwanted because during the polymerization step undesired cross-linked
byproducts can be formed. Afterwards, 2-(4-Hydroxybutyl)malonic Acid was hydrolyzed in
basic conditions utilizing NaOH as a base and a mixture of methanol/water. The new AB2
monomer holds three-bond connectivity with one OH- group and two COOH- groups in the
structure. The hydrolyze product (AB2 monomer) formed in step 2 is highly soluble in water.
However, when 2-(4-Hydroxybutyl)malonic Acid was subjected to melt-polymerization it
formed a water-insoluble polymer. This branch polymer holds ester linkages along its threedimensional polymeric backbone. The hyperbranched polyester features hydrophobic moieties
inside of the polymeric backbone and polar groups on the surface as represented in Figure 11.
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Figure 11.Representation of the Three Dimensional Structure of HBPE.

Characterization of Hyperbranched Polyester (HBPE)
Proton Nuclear Magnetic Relaxation (1H NMR)
Nuclear Magnetic Resonance (NMR) spectroscopy was selected as the analytical
technique for the determination of molecular structure as well as purity of products. Proton NMR
Spectra were analyzed and the corresponding structure was elucidated as shown in Figure 12.
Detailed below the corresponding proton NMR analysis for:
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1

(A) diethyl 2-(4-acetoxybutyl)malonate H NMR (500 MHz, CDCl3, δ ppm, JHz): 1.26 (t, 6H, J
= 7.6), 1.36 (m, 2H), 1.58 (q, 2H, J = 7.2), 1.96 (q, 2H, J = 7.7), 2.02 (s, 3H), 3.29 (t, 1H, J =
7.7), 4.04 (t, 2H, J = 6.6), 4.19 (q, 4H, J = 7.2).
1

(B) 2-(4-Hydroxybutyl)malonic Acid H NMR (500 MHz, DMSO-d6, δ ppm, JHz): 1.41 (m,
2H), 1.57 (m, 2H), 1.81 (q, 2H, J1 = 7.3, J2 = 7.8), 3.35 (t, 1H, J = 7.4), 3.62 (t, 2H, J = 6.5), 5.52
(bs, 1H).
1

(C) Hyperbranched Polyester (HBPE) H NMR 500 MHz, DMSO-d6, δ ppm: 1.24 (m, 2H), 1.51
(m, 2H), 1.66 (m, 2H), 3.37 (m, 1H), 3.57 (m, 2H), 5.28 (m, 1H).
1

The structure elucidation base on the

H NMR spectrum of diethyl 2-(4-

acetoxybutyl)malonate (Figure 12 A) confirmed the successful monoalkylation of diethyl
malonate with 4-bromobutylacetate. In comparison with the H1 NMR spectrum of 2-(4Hydroxybutyl)malonic Acid (Figure 12 B), the reduction of the ethyl ester protons (Hg) and the
acetyl group (Ha) confirmed the hydrolysis of diethyl 2-(4-acetoxybutyl)malonate. Furthermore,
Figure 12 C) shows a new broad pick (~ 4 Hz) that confirms a polymer structure that features a
polyester backbone. In greatly branched hyperbranched polyesters, the amount of dendritic units
is equivalent to the amount of terminal units. The integration ratio calculations between
methylene and methine protons, in the AB2 monomer and in HBPE based on 1H NMR data,
confirms that the number of terminal units were similar to that of dendritic units, implying the
growth of a highly branched HBPE polymer.
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Figure 12.1H NMR Spectra: A) monomer, B) the final AB2 monomer and C) HBPE.

Characterization of Functional HBPE Nanoparticles
The amphiphilic nature of this aliphatic polymer allows for the development of
multifunctional nanoparticles. Via solvent diffusion method, both the polymer and hydrophobic
cargos to be encapsulated were dissolved in water-miscible organic solvents. When dispersed in
water the miscible solvent rapidly diffuses into the water and triggers the polymer to selfassemble, revealing the hydrophilic segments and shielding the hydrophobic areas. During
assembly, the hydrophobic molecules are encapsulated and carboxylic acid moieties are expose
to the surface becoming available for further functionalization. First, we generated a library of
HBPE-COOH nanoparticles featuring a variety of cargos including: fluorescence dyes (DiI or
DiR), the cytotoxic peptide CT20 and its modifications (Rho-CT20p) or a combination of Dye
and CT20p. Since these nanoprecipitations are suspended in an aqueous environment they are
suitable for surface modifications via carbodiimide chemistry.

31

Carbodiimide chemistry provides a versatile method for the conjugation of the available
carboxylic acids with aminated small molecules. The water-soluble EDC was selected for
aqueous carbodiimide conjugation. MES buffer (4-morpholinoethanesulfonic acid) was used to
ensure slightly acidic conditions (pH=6.5) for a higher efficiency in the conjugation of EDC.
When added, EDC activates the carboxyl groups present on the surface of the HBPE
nanoparticle generating the O-acylisourea as intermediate. O-acylisourea is easily displaced by
nucleophilic attack from N-hydroxysuccinimide. N-hydroxysuccinimide (NHS) was added next
to generate an NHS ester, a more stable intermediate that is amine-reactive and a better living
group at physiologic pH. The activated NHS ester reacts with the primary amine and yields a
stable amide bond and the regeneration of N-hydroxysuccinimide (NHS). A zero-length
crosslinker (EDC) is very convenient in the process since there is a direct conjugation of
carboxylates (–COOH) to primary amines (–NH2) without becoming part of the final crosslink
(amide bond) between target molecules. This procedure was selected for the functionalization of
COOH-HBPE to yield folic acid and PEG decorated HBPE nanoparticles. As describe above the
HBPE nanoparticle preparations hold a series of hydrophobic fluorescent dyes (DiI and DiR)
and/or the cytotoxic peptide CT20p. The material was characterized and analyze as describe in
each section.

Infrared Spectroscopy
First, aminated folic acid was conjugated to the nanoparticle via carbodiimide chemistry
and the clean product was subjected to IR radiation. The resulting spectrum represents the
molecular absorption and transmission of the analyzed sample, creating a molecular fingerprint
of the sample. IR spectroscopy was used to identify functional groups within a given molecule.
The analysis of the spectrum bands, with characteristic intensities and frequencies, can be related
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to a specific functional group. Figure 13 displays the FT-IR spectra of COOH-HBPE
nanoparticles with characteristics bands at 1730 cm-1 and 2950 cm-1 confirms the presence of
carboxylic acid and ester groups on the nanoparticles structure. Otherwise, the FT-IR spectra of
Folate-HBPE(CT20p) NPs shows the reduction of the carboxylic acid characteristics peaks;
suggesting a successful conjugation of Folate-NH2 onto the nanoparticle surface.
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Figure 13.FT-IR spectra COOH-HBPE NPs, Folate-NH2 and Folate-HBPE(CT20p) NPs.

Transmission Electron Microscopy (TEM) Imaging
The size and the morphology of the Folate-HBPE(CT20p) NPs were assessed by
transmission electron microscopy (TEM). Moreover, Figure 14, a scanning transmission electron
microscopy (STEM) image of the Folate-HBPE(CT20p) nanoparticles corroborates the spherical
geometry of the nanoparticles. Exhibiting a well disperse sample preparation with nanoparticle’s
diameter within range of 80 to 100 nm.
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100
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Figure 14.Representative STEM image of Folate-HBPE(CT20p) NPs.

Dynamic Light Scattering Measurement
Dynamic light scattering (DLS) was later used to measure the size distribution of the
HBPE NPs nanoparticles. The different suspensions were summited to examination. Figure 15
shows an example the effective size as well as the size distributions of the preparations
suspended in ultra-pure water. Furthermore, the hydrodynamic size of the preparations used in
the course of this study was measured and reported in Table 1.
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Table 1.Hydrodynamic size measurements for HBPE NPs. Each measurement is
representative of the preparations used in the study.
Nanoparticle

Hydrodynamic Size (nm)

COOH-HBPE(CT20p)

73± 2

Folate-HBPE(CT20p)

89 ± 2

Folate-Peg-HBPE(CT20p)

104 ± 2

COOH-HBPE(DiI)

75 ± 2

Folate-HBPE(DiI)

90 ± 2

Folate-Peg-HBPE(DiI)

102 ± 2

COOH-HBPE(DiR)

81 ± 2

Folate-HBPE(DiR)

96 ± 2

Folate-Peg-HBPE(DiR)

108 ± 2

Dynamic light scattering (DLS) analysis confirmed the presence of stable and
monodispersed nanoparticle preparations. As shown in Figure 15, COOH-HBPE(CT20p) and
Folate-PEG-HBPE(CT20p) exhibited a hydrodynamic diameter of 73 nm and 104 nm,
respectively. The results demonstrated an increase in the size of the PEG/folate nanoparticle in
contrast carboxylated nanoparticle; a changed that was anticipated since we are adding new
functional groups to the surface of the carboxylated nanoparticle. Polydispersity index close to
0.1 indicated a monodisperse preparation. This behavior was consistence with all preparations as
demonstrated in Table 1.

Dynamic light scattering (DLS) was later used to measure the size

distribution of the HBPE NPs nanoparticles. The different suspensions were summited to
examination. Figure 15 shows an example the effective size as well as the size distributions of
the preparations suspended in ultra-pure water. Furthermore, the hydrodynamic size of the
preparations used in the course of this study was measured and reported in Table 1.
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A)

B)

Figure 15.Hydrodynamic size of A) COOH-HBPE(CT20p) NPs and B) Folate-PEGHBPE(CT20P) via DLS.
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Measurement of UV-Vis Spectra
Next, the optical characteristics of the HBPE NPs were examined by measuring their
absorption spectra. Figure 16 (A) shows the absorption spectra of COOH-HBPE(DiI) (black)
compare to DiI only (red) . COOH-HBPE(DiI) reveal a absorption peak at 553 nm, this findings
confirm de effective encapsulation of the desire dye. Moreover, the absorption spectra for other
dye encapsulated COOH-HBPE NPs were examine. Figure 16 (B) shows that in contrast to the
naked COOH-HBPE NPs (black), COOH-HBPE(DiI) (red) and COOH-HBPE(DiR) (blue)
display a absorption peak at 553 nm and 755 nm respectively. These peaks correspond to the
encapsulated dye (DiI or DiR) within the nanoparticle. This result indicated the enhanced
fluorescence property (imaging capability) of the nanocomposite.
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Figure 16.A) Comparison of the UV-Vis spectrum of COOH-HBPE(DiI) NPs and free DiI
dye in solution. B) UV-Vis spectra of different dye (DiI and DiR) encapsulated COOHHBPE NPs and COOH-HBPE NP.

Likewise, Folate-HBPE NPs were characterized using their UV-Vis spectra. Has been
reported that folic acid display a maximum absorption at ~ 363 nm.29 As shown in Figure 17 the
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spectrum for Folate-HBPE(DiI/CT20p) NPs (red) shows a peak at 370 nm confirming the
presence of folic acid. This result confirms along with the IR finds the successful conjugation of
folic acid and suggests the targetable capability of the nanocomposite.
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Figure 17.UV-Vis spectra of COOH-HBPE and Folate-HBPE(DiI/CT20p) NPs. The
characteristic absorption ~370 nm suggest the effective conjugation of Folic acid onto the
surface of the nanoparticle.

In Vitro Drug/Dye Release
To ensure an effective release of the drug from nanoparticle compartments, a FolateHBPE(Rho-CT20p) preparation was used. This nanoparticle contains a CT20p cytotoxic peptide
analog that contains a fluorescent dye (Rhodamine). This particular construct was monitor by
fluorescence spectroscopy and used to calculate the amount of cargo that was release from the
nanoparticle. The percentage of cumulative release was calculated applying equation 1. In
relation to the amount encapsulated during synthesis, nearly a 90 % of the peptide was liberated
from the cavities. As shown in Figure 18 minimal RHO-CT20p release was observed at
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physiological pH (pH=7.5) at any time point. Implicating that the HBPE nanoparticles are stable
under these conditions, while they are degraded under acidic conditions (pH=5.0). A cumulative
release of close to 90% was observed after 24h. These findings are significant for in vivo
applications since the nanoparticle localization in acidified compartments, such as lysosomes,
suggest the efficient drug release capability of our targetable Folate-HBPE nanoparticles.

Figure 18.Rate of release of CT20p at pH 5 and 7.4.

PSMA-Mediated Targeting and Cell Internalization of Folate-HBPE
NPs
Fluorescence Microscopy
The membrane localization of PSMA and its up-regulated expression in prostate cancer
cells makes PSMA a potential therapeutic target. The function of PSMA as a folate hydrolase has
been well documented9,38. To investigate if PSMA in prostate cancer cells can be targeted with
monoglutamated folate, LNCaP prostate cancer cells, which endogenously express PSMA, were
incubated with the fluorescence nanoparticle Folate-HBPE(DiI). Additionally, PC-3 prostate
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cancer cells were used as control cells as they do not express significant levels of PSMA. In
addition PSMA (+) PC3 cells were used to confirm the results. All incubations with FolateHBPE(DiI) were performed for a period of 24 h followed by fluorescence microscopy. LNCaP
and PC-3 are well-documented prostate cancer (PCa) cell lines derived from a different
metastatic site (lymph node and bone respectively). The DiI dye was visualized only in the
LNCaP and PC-3 PSMA(+) cell lines. Microscopy images (40x magnification), Figure 19 show
fluorescence in both the LNCaP and PSMA(+) cell lines; implying the internalization of the
Folate NPs thru the PSMA receptor.

A

B

C

Figure 19.Fluorescence microscopy of PCa cells: A) LNCaP, B) PC-3, and C) PSMA(+) PC3 upon 24 h incubation with Folate-HBPE(DiI) NPs. A 40x magnification lense was used;
these images are representative of the total area.

To further corroborate and to validate the receptor mediated mechanism for the
internalization of Folate-HBPE(DiI) NPs the PCa cell lines were evaluated in presence of a
PSMA inhibitor, PMPA. The PCa cell lines under study were treated with Folate-HBPE(DiI) and
assessed by FACS after 24 h. Fluorescence-activated cell sorting or FACS is a specific type of
flow cytometry that offers cell sorting based upon the specific light scattering and fluorescent
characteristics of each cell. The dot plots in Figure 20 demonstrate that Folate-HBPE(DiI) was
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uptake mainly by the PSMA(+) cell lines LNCaP and PSMA(+) PC-3. A shift to the right in the
dot plot means an increase in the intensity of the fluorescence form the uptake of FolateHBPE(DiI) NPs. No treated LNCaP and PC-3 (insert) are used as control; the dot plot (A)
displays an expected accumulation in bottom left due to no cell associated fluorescence emission
from DiI. Comparably, treated PC-3 (D) show low fluorescence from the uptake of FolateHBPE(DiI). Fluorescence microscopy confirms the minimal internalization of the construct as
exhibit in the insert (D). Minimal uptake can be explained by other internalization mechanisms
including endocytosis a common process were cells absorb molecules from surroundings by
engulfing them. Conversely, when LNCaP (B) and PSMA (+) PC-3 (E) were incubated with
Folate-HBPE(DiI) NPs both cell lines display a shift to the right in the dot plot due to a greater
cell associated fluorescence emission from the accumulation of DiI. Fluorescence microscopy
images, insert (B) and (E), confirm the accumulation of DiI within the cell (red), nuclei were
stain with DAPI in blue. In addition, the normal morphology of the all the cells after treatment
with Folate-HBPE(DiI) can be appreciated form the inserts. Furthermore, a highly potent and
selective inhibitor of PSMA was used to confirm that the uptake of the Folate-HBPE NPs
occurred thru targeting and mediated by PSMA receptor. PMPA was incubated with the PSMA
(+) cell lines an hour prior treatment with Folate-HBPE(DiI) NPs. Due to its high affinity for
PSMA receptor, PMPA inhibits the PSMA-mediated cell internalization of Folate-HBPE(DiI)
NPs as shown in Figure 20. Both cell lines, LNCaP (C) and PSMA(+) PC-3 (F), exhibit a shift to
the left in dot plot since there was not significant accumulation of the DiI. Fluorescence
microscopy images (insert (C) and (F)) corroborate the data and a minimal DiI fluorescence can
be located within the cell; comparable to the treated PSMA(-) PC-3 (D). These findings
implicate

that

PSMA

in

can

be

targeted
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Figure 20.Assessment of targeting and PSMA-mediated cell internalization of FolateHBPE(DiI) NPs by FACS analysis. Axis corresponding fluorescence; FL2-A = EtBr and Fl.
Intensity = DiI. A) Control, non-treated LNCaP and PC-3 (insert), B) LNCaP, C) LNCaP
pre-treated with PMPA. D) PC-3, E) PSMA(+) PC-3, F) PSMA(+) PC-3 pre-treated with
PMPA. Insert (B-E): Fluorescence microscopy images of the corresponding cells (40x
magnification lense).
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Folate-HBPE(CT20p) as Therapeutic Agent for PSMA(+) PCa Cell
Lines
Cell Viability: MTT Assay
Next, we evaluated the capability of delivering the therapeutic peptide CT20p to prostate
cancer cells via PSMA. CT20p has been identified as a potential therapeutic for metastatic breast
cancer cells.35 However, the targeted delivery of CT20p has not been achieved before. Therefore,
the targetable therapeutic nanoparticles Folate-HBPE (CT20p) and targeted control Folate-HBPE
were incubated for 48h with the PCa cell lines: LNCaP, PC-3 and PSMA(+) PC-3. The effect of
CT20p in the cell proliferation was assessed using MTT cell viability assay. First, PCa cell lines
where incubated for 48 h at different concentration of the CT20p. The targetable FolateHBPE(CT20p) NP was effective only to the PSMA (+) PCa cell lines: LNCaP and PSMA(+)
PC-3. Since the PC-3 cell line is PSMA receptor negative, minimal internalization of the
nanoconstruct was observed over a period of 24 h. Figure 21 (E) showed that at even at the
highest concentration of CT20p (12nM) PC-3 exhibits a 80% of cell viability. However, at the
highest concentration of CT20p (12nM) LNCAP (A) and PSMA(+) PC-3 (C) show a 12% and
25% of cell viability, respectively. As the CT20p concentration increased, the cell viability of
cancer cells was decreased for the PSMA(+) PCa cell lines. LNCaP and PSMA(+) PC-3 the IC50
value of CT20p in the Folate-HBPE(CT20p) NPs was calculated at 7nM. Then, all cell lines
where incubated with Folate-HBPE(CT20p) ( [CT20p] =7nM) over period of 48 h. As display in
Figure 21 (F) nearly 90% of the PC-3 cells were viable after 24 and 48 h of treatment with
Folate-HBPE(CT20p). In contrast, LNCaP (B) and PSMA(+) PC-3 (D) cells exhibit nearly 50%
cell death in 24 h and only ~ 15% of the cells were viable after 48h.
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Figure 21.Dose and time dependent cytotoxicity assay of PCa cells: LNCaP, PC-3 and
PSMA(+) PC-3 treated with Folate-HBPE(CT20p) NPs.
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Fluorescence Microscopy
A parallel assessment of Folate-HBPE(CT20p/DiI) NPs cellular uptake via fluorescence
microscopy using PCa cells was completed. Bright-field microscopy and corresponding merged
fluorescence images are summarize in Figure 22 Minimal internalization was observed in PC-3
cells treated with Folate-HBPE(CT20p/DiI) as no DiI fluorescence was observed in the
cytoplasm. Moreover, PC-3 bright-field images demonstrated no changes in the morphology or
the cell population. On the contrary, PSMA(+) PC-3 cells exhibit enhanced internalization upon
incubation with the Folate-HBPE(CT20p/DiI). As shown in Figure 22, after 48 h cells became
round and detached, resulting in a significant reduction of the cell population and indicating that
CT20p induced cell death and cause changes in cell morphology. These observations confirmed
the targeting capability and the receptor-mediated internalization of the Folate-HBPE(CT20p)
NPs together with the potential therapeutic capability of CT20p for PCa treatment.

Cell Viability: Flow Cytometry
Microcopy images along with MTT data show changes in proliferation and viability as
well as morphology in a time frame of 48h. To further investigated the effect of the peptide and
the receptor-mediated internalization of the construct, LNCaP Cells and RAW 264.7 cells
(macrophages) were incubated with Folate-HBPE(CT20p), and a series of controls for 48h .
Cells were stained with Sytox AADvanced and F2N12S dyes, and cell viability was assessed by
flow cytometry (Refer to Figure 23). The PCa cell line LNCaP endogenously overexpress the
PSMA(+) receptor, after 48h of treatment with Folate-HBPE(CT20p), CT20p affected the cell
population causing a shift to the left in the dot plot.
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Figure 22.Fluorescence microscopy of PCa cells: PC-3 and PSMA(+) PC-3 treated with
Folate-HBPE(CT20p/DiI)-NPs for 48h. (10x magnification lense)
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The PCa cell line LNCaP endogenously overexpress the PSMA(+) receptor, after 48h of
treatment with Folate-HBPE(CT20p), CT20p affected the cell population causing a shift to the
left in the dot plot. Three cell populations are identified and denoted as viable (bottom right
quadrant), apoptotic (bottom left quadrant), and necrotic (top left quadrant). Percentages of
viable cells (red) and combined apoptotic/necrotic cells (black) are shown. As shown in Figure
23) CT20p causes PCa cell-specific death; when macrophages were incubated with FolateHBPE(CT20p) there was no significant

change in cell viability. However, when the

macrophages where incubated with Doxorubicin (Doxo, a FDA approved drug for the treatment
of cancer) a dramatic change in cell viability was observed. A dramatic shift to the left region of
the dot plot show changes in viability due to cell dead by apoptosis and necrosis. In addition, the
targetable DOXO-SS-FOL also demonstrated to have a significant toxic effect in the cell
viability of macrophages. Furthermore, when Folate-HBPE(CT20p) was incubated in presence of
the PSMA inhibitor PMPA, the delivery of the peptide was restricted, validating the targetable
capability of the nanoparticle conjugates and the PSMA receptor-mediated internalization.

47

48h Folate-HBPE(CT20p)

48h DOXO

48h Untreated

48h Folate-HBPE(CT20p)

48h Folate-HBPE(CT20p) +PMPA

48h DOXO-SS-FOL

RAW 264.7

48h Untreated

LNCaP

Sytox

Necrotic

Apoptotic

Viable

Membrane Asymmetry

Figure 23.Viability assay by flow cytometry for LNCaP cells treated for 48 hours with Folate-HBPE(CT20p) NPs and RAW
264.7 cells (macrophages) treated for 48 hours with Folate-HBPE(CT20p), DOXO or DOXO-SS-FOL.
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CT20p Disrupts Cell Attachment and Reduces Integrin Levels in
PCa Cells
Following CT20p treatment, PSMA(+) PCa cells showed changes in morphology as well
as loss of cell adhesion. It was noticed that after a 24 h treatment with CT20p, cells started to
round up, detaching form the culture plate, floating, losing communication with adjacent cells
before dying in a period of 48 h. To measured the effect of CT20p in PCa cell lines after
treatment Folate-HBPE(CT20p) cells were assessed by crystal violet-based cellular adhesion
assay. Different form the PSMA(-) PC-3 cells that remained attached, LNCaP and PSMA(+)
PC-3 ~80% of cells detached from the substrate in the first 24 h of CT20p treatment as shown in
Figure 24(A). Furthermore, in a period of 48h, just ~ 50 % of the PSMA (+) cell remained
attached to the culture plate as shown in Figure 24(B-C). These results suggest an effect of
CT20p in the loss of attachment and communication of PSMA(+) cells line in vivo. Next, based
on these observations we investigated if the CT20p-mediated detachment of LNCaP and
PSMA(+) cells was accompanied by changes in the levels of integrins membrane receptors
involved in cell adhesion and recognition. PCa Cells: PC-3, PSMA(+) PC-3 and LNCaP were
treated with Folate-HBPE(CT20p) , CD29 (integrin β1) levels were assessed by flow cytometry
and presented in Figure 24 (D-F). Levels of integrin β1 are represented in a histogram in Figure
24 (D-F); a decrease in the levels of CD29 is presented as shift to the left (a decrease in the
fluorescence intensity associated to CD29). In LNCaP and PSMA(+) PC-3, but not PC-3 cells,
CD29 levels were altered after 24h of CT20p treatment. Furthermore, surface levels of β1 were
drastically decreased after 48 h in PSMA(+) PCa cell lines. Specifically, LNCaP shown the most
dramatic shift compare to PSMA(+) PC-3 whereas PC-3 shown no change. The difference in the
effect of Folate-HBPE(CT20p) between LNCaP and PC-3 PSMA(+) can be attribute to changes
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in PSMA receptor expression. Lost of expression can occur after several passages during cell
culture considering that PSMA(+) PC-3 was genetically modify to express PSMA while LNCaP
endogenously over express PSMA. The observed decrease in the levels of β1 integrin expression
by flow cytometry at 24 h and 48 h post CT20p treatment agree with the observed changes in cell
adhesion. Since β1 integrin (CD29) is known to be involved in cell adhesion and only PSMA(+)
cell lines were affected post treatment with Folate-HBPE(CT20p); these data implies that CT20p
is somehow responsible for the decrease in the expression of CD29 and that in fact this changes
are in part responsible for causing CT20p-mediated cell detachment and death.
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Figure 24.Integrin levels in D) PC3, E) PSMA(+) PC3 and F) LNCaP treated with FolateHBPE(CT20p) and corresponding percent of cell adhesion (A-C).
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CT20p Causes PCa Cell Death in vivo
To assessed the capacity of CT20p to act as a therapeutic agent in vivo in a murine
prostate tumor model together with the PSMA receptor-mediated internalization of FolateHBPE(CT20p) PCa cells: PC-3, PSMA(+) PC-3 and LNCaP were subcutaneously implanted in
Foxn1nu/Foxn1nu mice, and tumor growth was monitored. To improve circulation and prevent
uptake by the reticuloendothelial system, pegylated nanoparticles were used. To confirm the
ability to target the PSMA receptor in vivo, mice received intravenous (IV) injections of FolatePEG-HBPE(DiR) and visualize in a Perkin Elmer’s In Vivo Imaging System (IVIS) 24 h posttreatment. Figure 25 (A) show a strong signal coming from the PSMA(+) PC-3 tumor (right
flank) while no signal was detected from PSMA(-) PC-3 tumor (left flank). A localize signal
validate the PSMA receptor-mediated tumor localization in a murine prostate tumor model.
Additionally, groups of mice with tumors were given two sets of IV injections of Folate-PEGHBPE(CT20p) (20 μg of CT20p dose) in a period of 14 days. Post-treatment tumor size was
monitored by ultrasound imaging after 10 days, a representative experiment is exhibit in Figure
25 (B). In addition, caliper measurements were recorded daily and the changes in tumor area
post-treatment were graphed and presented in Figure 25 (C). When CT20p in Folate-PEG-HBPE
NPs was delivered to PSMA(+) PC-3 tumors, tumor growth was inhibited (refer to ultrasound
images in Figure 25 (B)) and in most cases exhibited significant tumor regression as shown in
the tumors excised from mouse #2.Meanwhile, PSMA(-) PC-3 tumors continued to grow. Figure
25 (C) shows that Folate-PEG-HBPE(CT20p) NPs are only effective when CT20p is deliver by
PSMA receptor-mediated internalization. Hematoxylin & eosin (H & E) stained sections of the
liver and spleen (area that HBPE-NPs can concentrate), from mice treated with Folate-PEG-
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HBPE(CT20p) NPs were assessed by a pathologist and found to have no evident signs of
necrosis or damage, while targeted tumor tissue exhibit regions of necrosis.
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Figure 25.Mice were injected subcutaneously (SC) with PSMA (+) (right flank) or PSMA(-) (left flank) PCa tumor cells. Upon
tumor detection (~2 weeks), mice were injected intravenously (IV) with Folate-PEG-HBPE-NPs (2mg/kg/dose) containing a A)
DiR or B) CT20p. A) Mice were imaged after 24 hours or sacrificed after 10 days. C) Progression of the tumor growth (area)
post-treatment. D) Tissue was harvested from B) for histological examination by a pathologist. Detection of necrotic and
fragmented tissue in the PSMA(+) tumor is indicated by arrow and borders demarked by line.
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Similarly, the capacity of CT20p to act as a therapeutic agent in vivo on LNCaP cells was
investigated. LNCaP cells were subcutaneously implanted in mice. Groups of mice with grown
LNCaP tumors were injected intravenously (IV) with Folate-PEG-HBPE(CT20p) (150 μg of
CT20p) NPs or PBS as a control. Caliper measurements were taken daily and the data is
presented in Figure 26 (A). At completion of the experiment mice were weighed and tumors
were removed and weighted as well. As shown in Figure 26 (A-B) LNCaP tumors treated with
Folate-PEG-HBPE(CT20p) prevented tumor growth. This is in contrast to tumors injected with
PBS where the tumor size increased post-treatment. Also, Figure 26 (D) supports the effect of
CT20p when comparing the tumor weight. A noticeable inhibition of growth is characteristic of
LNCaP tumors treated with Folate-PEG-HBPE(CT20p) different form PBS treated tumors.
These results indicate that CT20p encapsulated in folate decorated nanoparticles can target
PSMA(+) tumors and is a promising alternative as a therapeutic agent.
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A)

B)

C)

D)

Figure 26.Folate-PEG-HBPE(CT20p) treatment impairs growth of LNCaP tumors
implanted in mice.
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CHAPTER FOUR: CONCLUSIONS
We demonstrated the effective use of the therapeutic peptide CT20P derived from the
endogenous protein Bax using a targetable delivery strategy. In our studies, we used HBPE NPs
conjugated to the targeting ligand Folate to guide them to specific cell surface targets, PSMA.
We have demonstrated that Folate-HBPE NPs targets PSMA to facilitate internalization into
prostate cancer cells.. Moreover, the used of targetable strategies lead us to study the effect of
folate-HBPE(CT20p) over PCa cell lines in vitro . We determine that the IC50 for PSMA(+) PCa
cell lines (LNCaP and PSMA(+) PC- 3) to be ~7nM. Whereas the well-documented FDA
approve doxorubicin requires ~100x higher dose to ensure the same deadly effect. Moreover,
CT20p does not affect normal cells like macrophages as opposed to doxorubicin that kill these
cells. It was establish that the CT20p causes cell death in 48 h and decreases CD29 levels within
24 h (an integrin involve in cell adhesion) and therefore causing cell detachment in the first 24 to
48 h. Folate-HBPE(CT20p) NPs shown no effect against macrophages or PC-3 cells, showing
the effective targetable approach of the construct. Lastly, we investigated the performance of
Folate-HBPE(CT20p) in vivo in a murine prostate tumor models. The Folate-HBPE-NPs locked
CT20p while in circulation and allowed efficient uptake by targeting tumor cells via PSMA.
CT20p shows the capability to perform as a potent therapeutic agent in vivo when studying PCa
tumor models. These findings demonstrate that CT20p delivered by folate-functionalized
nanoparticles can target PSMA positive tumors in vivo and perform as an anticancer treatment.
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